M. Willy Honders - Concepedia

Author

M. Willy Honders

Leiden University Medical Center

Also Known As

M W Honders, M Willy Honders, M. W. Honders, M. Willy Honders, M.W. Honders, M.Willy Honders, MW Honders

Publications

693

Citations

H-Index

Concepts

All Affiliations

Leiden University Medical Center Radboud University Nijmegen Radboud University Medical Center Radboud Institute for Molecular Life Sciences Universitätsklinikum Erlangen

About

M. Willy Honders is an author at Leiden University Medical Center specializing in medicine, cell biology, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	138
2	Cell Biology	4	4	138
3	Cellular Therapies	2	2	86
4	Immunology	2	2	86
5	Biochemistry	1	1	16

M. Willy Honders

Publications

617

Citations

H-Index

Page 1

	Year	Citations
Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing Wibowo Arindrarto, Daniel Borràs, Ruben A. L. de Groen, Leukemia	2020	100
High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia Marjan J. T. Veuger, M. Willy Honders, Jim E. Landegent, Blood	2000	83
Identification of phosphatidylinositol 4-kinase type II β as HLA class II-restricted target in graft versus leukemia reactivity Marieke Griffioen, Edith D. van der Meijden, Elisabeth H. Slager, Proceedings of the National Academy of Sciences HistocompatibilityCell TherapyHla ImmunogeneticsImmunologyPathology	2008	67
Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer Elisabeth H. Slager, M. Willy Honders, Edith D. van der Meijden, Blood	2006	65
Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells Marjan J. T. Veuger, Mirjam H.M. Heemskerk, M. Willy Honders, Blood	2002	56
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene Alexander P.A. Stegmann, M. Willy Honders, A Hagemeijer, Annals of Hematology Hematological MalignancyMolecular PharmacologyVitro-induced ResistanceAcute Myeloid LeukemiaMedicine	1995	36
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. Alexander P.A. Stegmann, M. Willy Honders, M. G. D. Kester, PubMed	1993	34
Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity Marieke Griffioen, M. Willy Honders, Edith D. van der Meijden, Haematologica	2012	33
Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia Marjan J. T. Veuger, M. Willy Honders, Roel Willemze, European Journal Of Haematology	2002	27
De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC). Alexander P.A. Stegmann, M. Willy Honders, R. Willemze, PubMed	1995	27

Page 1